GKB7I-53:一种用于结直肠癌的新型抗转移剂
Min Hee Yang1, Ducdat Le2, Thinhulinh Dang3
1Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
Toxicology and applied pharmacology
|January 14, 2026
概括
一种新型的素化合物,GKB7I-53,通过向表皮-介质细胞转换 (EMT) 途径而有效地抑制结直肠癌转移,而没有显著的细胞毒性. 需要进一步的研究来验证治疗效果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由表皮-介质细胞过渡 (EMT) 驱动的结肠直肠癌转移是一个重要的治疗挑战.
- 针对EMT途径提供了一个有希望的策略来抑制癌症的进展和传播.
研究的目的:
- 为了研究GKB7I-53的潜力,一个素化合物,作为一种针对结直肠癌EMT的抗转移剂.
- 阐明GKB7I-53对EMT和转移的作用背后的分子机制.
主要方法:
- 基于特征的分子网络用于化合物隔离.
- 在体外测试以评估细胞毒性,细胞迁移,入侵和MMP-2/9活动.
- 对表皮和介质细胞标记物表达的分析.
- 对JAK/STAT3信号通路和MnSOD参与的调查.
- 分子对接研究. 分子对接研究.
主要成果:
- GKB7I-53表现出最小的细胞毒性,并通过降低介质细胞标记物 (CXCR4,CXCR7) 和上调表皮细胞标记物 (E-cadherin,occludin) 来有效抑制EMT.
- 该化合物显著降低了细胞迁移和入侵,并抑制了CXCL12刺激细胞中的MMP-2/9活性.
- GKB7I-53抑制了MnSOD诱导的STAT3激活,阻止了对转移至关重要的JAK/STAT3通路.
- 分子对接证实了与EMT相关的标蛋白具有强烈的结合亲和力.
结论:
- 通过选择性调节EMT通路,GKB7I-53在结直肠癌中显示出强大的抗转移性质.
- 该化合物通过抑制JAK/STAT3信号通路而起作用,提供了一种新的治疗方法.
- GKB7I-53作为结直肠癌治疗的主要化合物具有前景,因此需要进一步进行体内和临床前的研究.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
602
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
602
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
588
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
588


